Bristol Myers Squibb stock gains as pipeline news and 2026 guidance support outlook

Bristol Myers Squibb stock (ISIN US1101221083) closed at USD 63.06 on the New York Stock Exchange on September 18, 2026, marking a modest single-session gain that left the shares trading between their 52-week low and high as investors weigh new pipeline developments against the company’s updated 2026 guidance.

Pipeline signals drive attention

As Chosun Ilbo reported on September 21, 2026, Bristol Myers Squibb has decided to discontinue development of the acute myeloid leukemia candidate BMS-986497 (also known as ORM-6151), which in turn led to the early termination of a 2023 asset transfer agreement with Orum Therapeutics that had carried a potential value of up to USD 180 million.

According to the same Chosun Ilbo coverage, Orum Therapeutics will not receive the up to USD 80 million in milestones originally envisioned under the collaboration, although there is no obligation to return the USD 100 million upfront payment already recorded, illustrating how Bristol Myers Squibb’s R&D decisions can materially affect smaller partners while leaving its own balance sheet largely intact in this specific case.

Pipeline news has also brought positive signals: a report summarized by Ad-hoc-news on September 21, 2026 highlighted that Bristol Myers Squibb’s oral CELMoD agent mezigdomide achieved positive phase 3 SUCCESSOR-2 results in relapsed or refractory multiple myeloma, meeting its primary endpoint of improved progression-free survival versus a standard regimen, which could help offset concerns around individual program discontinuations.

Revenue, earnings and 2026 guidance

Beyond individual trial headlines, investors are focusing on the company’s latest financial performance and guidance. According to an in-depth analysis from StocksDownUnder on September 20, 2026, Bristol Myers Squibb generated revenue of USD 11.5 billion in the first quarter of 2026 and USD 13.0 billion in the second quarter of 2026, representing year-over-year growth of about 3 percent in Q1 and 6 percent in Q2.

The same StocksDownUnder piece notes that Bristol Myers Squibb’s Growth Portfolio, which includes drugs such as Camzyos, Reblozyl, Breyanzi, Opdualag and expanded Opdivo indications, delivered revenue increases in the range of roughly 12–15 percent across the first half of 2026, while its Legacy Portfolio, led by Revlimid and Pomalyst, saw revenue declines of about 4–6 percent over the same period.

Importantly for valuation, the company has raised its full-year 2026 guidance: according to StocksDownUnder, Bristol Myers Squibb now expects 2026 revenue of USD 49–50 billion and non-GAAP earnings per share of USD 6.75–7.00, which, at the midpoint, implies high-single-digit to low-double-digit earnings growth compared with prior years despite mounting price pressure and looming patent expirations.

A separate overview of recent results cited by MSN on September 20, 2026 points out that Bristol Myers Squibb reported second-quarter 2026 revenue of USD 12.9 billion, up 6 percent year over year, and earnings per share of USD 1.62, an increase of 153 percent compared with the same quarter a year earlier, while generating more than USD 3 billion in free cash flow, underscoring a strong ability to fund both R&D and shareholder returns.

Analyst sentiment and patent-cliff risk

On the sentiment side, Bristol Myers Squibb is not seen as a pure turnaround story but rather as a mature pharmaceutical group balancing growth and erosion. According to StocksDownUnder, consensus expectations for 2026 call for revenue growth of roughly 20–25 percent across the mid-decade years when including newer assets, even as Bristol Myers Squibb faces a significant patent cliff for its blockbuster therapies.

The same StocksDownUnder analysis stresses that one of the company’s most important franchises faces staggered loss of exclusivity, with Europe expected to lose exclusivity in 2026, Japan in 2027 and the United States in 2028, and by 2031 revenue erosion for that segment could approach 98 percent, illustrating why investors scrutinize each new pipeline success and guidance update particularly closely.

Reflecting a constructive view on earnings power, Zacks noted on September 21, 2026 that Bristol Myers Squibb carries a Zacks Rank of 2 (Buy), with the consensus estimate for full-year earnings having moved about 10 percent higher over the past quarter and the shares returning approximately 16.5 percent year to date, a performance that outpaces many broader medical-sector peers.

Consensus valuation metrics discussed by StocksDownUnder further show that market expectations for fiscal year 2027 stand at roughly USD 48.2 billion in revenue and normalized earnings per share of about USD 5.63, providing investors with a numerical framework to compare the current 2026 guidance to projected post-patent-cliff earnings power.

Stock price, trading range and market metrics

Per recent exchange data summarized by Ad-hoc-news on September 21, 2026, Bristol Myers Squibb stock closed at USD 63.06 on the New York Stock Exchange on September 18, 2026, with an intraday low of USD 62.19 and a session high matching the closing price of USD 63.06; that level places the shares between their 52-week low of USD 42.53 and 52-week high of USD 68.64, meaning the current price sits roughly mid-range between the extremes over the past year.

The same Ad-hoc-news report, citing data compiled as of September 18, 2026, indicated that trading volume reached 36,576,219 shares in that session, while price data from CNBC for the same day show that the closing price of USD 63.06 represented a gain of about 0.35 percent compared with the prior close, suggesting steady, if unspectacular, buying interest after the latest flow of news.

For investors, this combination of a mid-range price level between the 52-week low of USD 42.53 and high of USD 68.64, a year-to-date return of around 16.5 percent, and upgraded guidance to 2026 revenue of USD 49–50 billion and non-GAAP EPS of USD 6.75–7.00 means that Bristol Myers Squibb stock is being priced for continued execution, with pipeline successes such as mezigdomide’s phase 3 SUCCESSOR-2 result providing potential upside while decisions like halting BMS-986497 highlight the ongoing selectivity in capital allocation.

Closing view on Bristol Myers Squibb stock

As of the last completed New York Stock Exchange session on September 18, 2026, Bristol Myers Squibb stock traded at USD 63.06 in United States dollars, a level that leaves the shares comfortably above their 52-week low of USD 42.53 but still below the 52-week high of USD 68.64, reflecting a market that is cautiously optimistic about the company’s raised 2026 guidance and strengthening growth portfolio, yet mindful of the sizeable patent-cliff and R&D risks that will shape the long-term trajectory.

More news and analyses on Bristol Myers Squibb stock